Bryan Jones
Chief Operating Officer Aardvark Therapeutics
Seminars
Thursday 16th April 2026
Redefining the Patient Experience with a First-in-Class Oral, Gut- Restricted Agonist to Improve Tolerability
2:00 pm
- Utilizing an oral, non-systemic bitter taste receptor (TAS2R) agonist to bypass the need for injections and transform the route of administration for metabolic therapeutics
- Stimulating the body’s own endogenous secretion of multiple gut hormones locally in the GI tract to achieve a more physiological response with superior gastrointestinal tolerability
- Enhancing long-term patient adherence and quality of life by providing a simple, pill based therapeutic option that avoids injection-site reactions and systemic side effects
